Wellington Management Group LLP Lowers Stock Holdings in Agilent Technologies, Inc. $A

Key Points

• Wellington Management Group LLP sold 376,026 shares of Agilent Technologies, Inc., reducing its stake by 4.0% in the first quarter, now holding 8,930,779 shares valued at approximately $1.04 billion.
• Agilent Technologies reported earnings of $1.31 per share for the last quarter, exceeding expectations and showing a 6.0% revenue increase year-over-year, totaling $1.67 billion.
• The company recently announced a quarterly dividend of $0.248 per share, representing an annualized yield of 0.8%, with a dividend payout ratio of 24.44%.

Wellington Management Group LLP decreased its holdings in Agilent Technologies, Inc. (NYSE:A - Free Report) by 4.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 8,930,779 shares of the medical research company's stock after selling 376,026 shares during the quarter. Wellington Management Group LLP owned 3.13% of Agilent Technologies worth $1,044,723,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. raised its holdings in Agilent Technologies by 13.5% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,674 shares of the medical research company's stock worth $4,279,000 after purchasing an additional 4,362 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of Agilent Technologies by 8.3% during the first quarter. Assenagon Asset Management S.A. now owns 30,827 shares of the medical research company's stock valued at $3,606,000 after acquiring an additional 2,371 shares during the last quarter. Alps Advisors Inc. raised its holdings in shares of Agilent Technologies by 29.5% during the first quarter. Alps Advisors Inc. now owns 13,358 shares of the medical research company's stock valued at $1,563,000 after acquiring an additional 3,040 shares during the last quarter. D.A. Davidson & CO. raised its holdings in shares of Agilent Technologies by 30.4% during the first quarter. D.A. Davidson & CO. now owns 9,474 shares of the medical research company's stock valued at $1,108,000 after acquiring an additional 2,207 shares during the last quarter. Finally, LGT Capital Partners LTD. raised its holdings in shares of Agilent Technologies by 7.6% during the first quarter. LGT Capital Partners LTD. now owns 768,252 shares of the medical research company's stock valued at $89,870,000 after acquiring an additional 54,302 shares during the last quarter. Institutional investors and hedge funds own 87.41% of the company's stock.

Agilent Technologies Trading Up 3.7%

Shares of A traded up $4.3420 during midday trading on Friday, hitting $121.4920. 1,290,972 shares of the stock were exchanged, compared to its average volume of 1,284,543. Agilent Technologies, Inc. has a 52-week low of $96.43 and a 52-week high of $153.84. The stock has a fifty day simple moving average of $117.88 and a 200 day simple moving average of $117.47. The firm has a market cap of $34.51 billion, a P/E ratio of 30.00, a P/E/G ratio of 3.55 and a beta of 1.22. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.60 and a current ratio of 2.09.

Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings data on Wednesday, May 28th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.05. The business had revenue of $1.67 billion for the quarter, compared to analysts' expectations of $1.63 billion. Agilent Technologies had a return on equity of 25.92% and a net margin of 17.59%.The company's revenue for the quarter was up 6.0% compared to the same quarter last year. During the same period last year, the firm earned $1.22 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.540-5.610 EPS. Q3 2025 guidance at 1.350-1.370 EPS. On average, research analysts anticipate that Agilent Technologies, Inc. will post 5.58 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Padraig Mcdonnell sold 1,508 shares of Agilent Technologies stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total transaction of $177,099.52. Following the sale, the chief executive officer owned 37,448 shares in the company, valued at approximately $4,397,893.12. The trade was a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.26% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. TD Cowen increased their target price on Agilent Technologies to $150.00 and gave the company a "buy" rating in a report on Thursday, May 29th. Wall Street Zen raised Agilent Technologies from a "hold" rating to a "buy" rating in a report on Saturday, June 28th. UBS Group cut their price target on Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating for the company in a report on Thursday, May 29th. Robert W. Baird reduced their price objective on Agilent Technologies from $159.00 to $140.00 and set an "outperform" rating on the stock in a research report on Thursday, May 22nd. Finally, Barclays lifted their price objective on Agilent Technologies from $115.00 to $125.00 and gave the stock an "equal weight" rating in a research report on Tuesday, June 24th. Seven analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $139.77.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.